Elutia Q4 revenue rises on higher cardiovascular product sales

Elutia

11/03/2026 20:26

Overview

Drug-eluting biomatrix maker's Q4 revenue rose 16% yr/yr to $3.3 mln

Net income turned positive, driven by $88 mln BioEnvelope business sale to Boston Scientific

Company repaid all outstanding debt and ended year with $44.4 mln in cash and escrowed proceeds

Outlook

Elutia anticipates FDA clearance for NXT-41 in second half of 2026

Company expects full NXT-41x clearance in first half of 2027

Result Drivers

PRODUCT MIX - Cardiovascular product sales rose, offsetting a decline in SimpliDerm sales

GROSS MARGIN IMPROVEMENT - Gross margin increased due to lower cost of goods sold

Company press release: ID:nGNXF1lsz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Miss*
$3.27 mln
$3.30 mln (1 Analyst)
Q4 EPS
$1.48
Q4 Net Income
$70.79 mln
Q4 Gross Profit
$1.91 mln
Q4 Operating Expenses
$8.48 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Elutia Inc is $5.00, about 358.7% above its March 10 closing price of $1.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)